Form D · Pharmaceuticals

SpringLeaf Therapeutics, Inc.

Boston, MA · CIK 0001413681

Offering snapshot reported Jul 8, 2011 · SEC filing

Reported sold: $19M
Investors reported: 8
Minimum accepted: $0
First sale: Apr 28, 2011

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$15,037,500 → $19,047,501
Reported investors6 → 8

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Jul 8, 2011	Amendment	$19,047,501	$4,010,001vs May 12, 2011	8	SEC filing
May 12, 2011	Initial	$15,037,500	No comparison	6	SEC filing
Dec 5, 2008	Paper	Not reported	No comparison	Not reported	SEC filing
Sep 26, 2007	Paper	Not reported	No comparison	Not reported	SEC filing

Offering details

Securities: Equity, Other
Exemptions: 06
Duration over one year: No
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-159732

Series B Preferred Stock

Source: Form D, filed Jul 8, 2011. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Frank Bobe	Director, Executive
Garen Bohlin	Director
Yet Ming Chiang	Director
Michael Cima	Director
Brian Gallagher	Director
Kurt Graves	Director
Michael Greeley	Director
Glenn Larsen	Executive
Jeffrey Mc Carthy	Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:

8 St. Mary's Street Suite 601
Boston, MA, 02215